The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 25, 2022
Filed:
Jul. 28, 2020
Applicant:
Biomarin Pharmaceutical Inc., Novato, CA (US);
Inventors:
Thomas Lester, Castro Valley, CA (US);
Saeed Moshashaee, San Rafael, CA (US);
Augustus O. Okhamafe, Concord, CA (US);
Charles A. O'Neill, Vineburg, CA (US);
Assignee:
BIOMARIN PHARMACEUTICAL INC., Novato, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/198 (2006.01); A61P 25/28 (2006.01); A61K 38/48 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); C12N 9/48 (2006.01); A61M 5/14 (2006.01); A61K 9/08 (2006.01);
U.S. Cl.
CPC ...
A61K 38/4813 (2013.01); A61K 9/0085 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61M 5/14 (2013.01); C12N 9/485 (2013.01); A61K 9/0048 (2013.01); C12Y 304/14009 (2013.01);
Abstract
Formulations comprising recombinant human tripeptidyl peptidase-1 (rhTPP1) for intrathecal, intracerebroventricular, or intraocular administration, and kits comprising the same, are disclosed. Methods of using rhTPP1 in the prevention and treatment of symptoms of Neuronal Ceroid Lipofuscinosis (CLN2) disease are also disclosed. The formulations and methods are effective in halting the progression of CLN2 disease and may be used to treat subjects having CLN2 or a family history of CLN2.